<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586117</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-022</org_study_id>
    <nct_id>NCT01586117</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity</brief_title>
  <official_title>A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of intrarectal Amifostine administration
      on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the different use way of intrarectal Amifostine administration on acute
      radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute radiation-induced toxicity: daily diarrhea frequency</measure>
    <time_frame>about 3 months from chemo-raditherapy to operation</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Amifostine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intrarectal Amifostine assign to the Amifostine arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifostine</intervention_name>
    <description>intrarectal Amifostine administration 1500mg QD x 5 weeks</description>
    <arm_group_label>Amifostine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically confirmed rectal cancer, preoperative stage II / III (T3-4N0 or T1-4N +
             M0).

          -  tumor distance from anus less than 12 cm.

          -  KPS score not less than 70

          -  can be tolerated chemotherapy and radiotherapy.

          -  pelvic who had no history of radiation therapy.

          -  Non-allergic history of fluorouracil or platinum-based chemotherapy drugs.

          -  blood pressure can be controlled by drugs in the normal range (90 ≤ systolic blood
             pressure ≤ 140,60 ≤ diastolic blood pressure ≤ 90).

          -  a full understanding of the study, the ability to complete all of the treatment plan,
             follow up the conditions and sign the informed consent.

        Exclusion Criteria:

          -  other malignancy (past or at the same time), does not include curable non-melanoma
             skin cancer and cervical carcinoma in situ; does not include resectable primary colon
             cancer (synchronous or metachronous).

          -  pregnant or lactating patients.

          -  fertility but did not use contraceptive measures.

          -  existing active infection.

          -  merge serious complications, can not tolerate the treatment, such as 6 months of
             myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable
             hypertension or hypotension.

          -  concurrent treatment with other anticancer drugs.

          -  can not complete treatment or follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Jin, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Acedemy of Medical Scinences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Li, MD</last_name>
    <phone>86-13810381399</phone>
    <email>lee_ak@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radiation Oncology Depratment, Cancer Hospital, CAMS</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, MD</last_name>
      <phone>86-13810381399</phone>
      <email>lee_ak@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>M.D. Cancer Hospital, CAMS</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>amifostine</keyword>
  <keyword>pre-operative chemo-radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

